The Human Variable 

FEMA’s flood plans overlook infection-associated chronic conditions now affecting one-quarter of U.S. adults. This CYNAERA white paper introduces biologic disaster modeling using US-CCUC™, ESA™, VitalGuard™, and MoldX™ to forecast medical surges from mold, heat, and power loss. Applying these systems could prevent 70 percent of non-trauma ER visits and save $7.4 billion annually in federal costs.

Traditional medicine isolates diagnoses by organ or specialty. CYNAERA’s terrain logic views the body as an interdependent system where immune, endocrine, and autonomic signals co-determine stability. The Playbook applies three key insights from the Primary Chronic Trigger (PCT) Blueprint. Chronic illness begins with temporal ignition, an event that tips an unstable terrain. Chronicity persists when recovery conditions (RC) remain incomplete.

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is profoundly sensitive to environmental stressors. Pollutants such as polycyclic aromatic hydrocarbons (PAHs), particulate matter (PM₂.₅, PM₁₀), nitrogen dioxide (NO₂), ground-level ozone (O₃), sulfur dioxide (SO₂), and volatile organic compounds (VOCs), combined with weather triggers like heat, cold, barometric pressure swings, mold, humidity, and pollen, drive flares that push patients into cycles of severe disabi

Contrary to the conventional framing of remission as spontaneous or unachievable, this framework presents remission as a predictable biological outcome, emerging from synchronized interventions across immune, hormonal, mitochondrial, and environmental axes. The CYNAERA Remission Pathway™ outlines a five-phase stabilization and recovery model, while the STAIR: Stable Method™ offers pre-intervention protection for hypersensitive subgroups, including those with mast cell reacti

This future ready framework was built from real world data, patient-led insights and cutting-edge biomarker science. 35–50 million Americans. 25–30% global prevalence. $1 trillion annual impact. The world can’t afford diagnostics that guess, it needs diagnostics that know. Read the groundbreaking Composite Diagnostic Fingerprint for Long COVID, authored by patient-turned-subject matter expert Cynthia Adinig. Nobel Prize worthy thinking. Welcome to CYNAERA. Where technology m